I suspect that we will see panic selling this morn
Post# of 148173
That said, this type of response from the FDA is completely normal. It's frustrating, but common.
It delays HIV revenue, but has no impact on our COVID trials which, may take all available inventory for the near term anyway.
I am frustrated by this, but primarily because of the anticipated reaction of the shareholders and shorts. (I'm also not looking forward to hearing Nader's explanation)